WTIM
SLXP

Wilmington Trust Investment Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Wilmington Trust Investment Management’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$210K Buy
+1,700
New +$188K 0.04% 347

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wilmington Trust Investment Management's SLXP Position: Q2 2014 in Review

Wilmington Trust Investment Management opened a new position in SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2014: 1,700 shares worth $210K. The stake represents 0.04% of the portfolio and ranks #347 among its holdings.

308 funds tracked by Wall St. Rank hold SLXP as of Q2 2014.

  • Wilmington Trust Investment Management held 1,700 shares of SALIX PHARMACEUTICALS LTD DEL worth $210K as of Q2 2014.
  • SALIX PHARMACEUTICALS LTD DEL was a new Wilmington Trust Investment Management position in Q2 2014.
  • SALIX PHARMACEUTICALS LTD DEL made up 0.04% of Wilmington Trust Investment Management's portfolio in Q2 2014, its #347 holding.
  • 308 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2014.

Based on Wilmington Trust Investment Management's 13F filing for Q2 2014, filed 13 Aug 2014.